Benzoic acid derivatives as modulators of ppar alpha and gamma

Abstract

A compound of formula (I) wherein Rrepresents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group —(CH)-T-(CH)—U—(CH— is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH), O(CH), NC(O)NR(CH), CHS(O)NR(CH), CHN(R)C(O)CH, (CH)N(R)C(O)(CH), C(O)NRCH, C(O)NR(CH), and CHN(R)C(O)CHO; V represents O, S, NRor a single bond; q represents 1, 2, or 3; W represents O, S, N(R)C(O), NR, or a single bond; Rrepresents halo, a Calkyl group which is optionally substituted by one or more fluoro, a Calkoxy group which is optionally substituted by one or more fluoro, a Cacyl group, aryl, an aryl Calkyl group, CN or NO; r represents 0, 1, 2 or 3; Rhalo, a Calkyl group which is optionally substutited by one or more fluoro, a Calkoxy group which is optionally substituted by one or more fluoro, a Cacyl group, aryl, an aryl Calkyl group, or CN; s represents 0, 1, 2 or 3; and R, R, R, R, R, R, and Rindependently represent H, a Calkyl group, aryl or an aryl Calkyl group or when m is O and T represents a group N(R)C(O) or a group (R)NS(O) then Rand Ror Rand Rtogether with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.